A5027503520- Gastric Cancer Management and Outcomes
- Economic and Financial Impacts of Cancer
- Fibroblast Growth Factor Research
- Innovations in Medical Education
- Advances in Oncology and Radiotherapy
- Metastasis and carcinoma case studies
- Pulmonary Hypertension Research and Treatments
- Diversity and Career in Medicine
- Molecular Biology Techniques and Applications
- Biological Research and Disease Studies
- Gastrointestinal Tumor Research and Treatment
- Healthcare professionals’ stress and burnout
- Cancer Immunotherapy and Biomarkers
- Tannin, Tannase and Anticancer Activities
- Reproductive Biology and Fertility
- Renal cell carcinoma treatment
- Cancer Diagnosis and Treatment
Tashkent State University of Law
2024-2025
478 Background: Data on site-specific progression patterns in metastatic renal cell carcinoma (mRCC) treated with immuno-oncology agents are limited. This study aimed to characterize sites of patients receiving nivolumab plus ipilimumab (Nivo-Ipi) or axitinib-based immunotargeted combinations the first-line setting. Methods: A retrospective, observational cohort included clear-cell mRCC who received either Nivo-Ipi (Cohort A) pembrolizumab-axitinib and avelumab-axitinib B) from 2018 2024....
Relevance: The problem of reproductive health women suffering from oncological diseases is becoming increasingly important in the context modern healthcare. Breast cancer diagnosed young age, which creates a need to study impact these on ovarian reserve, critical for ability conceive. This aimed assess breast reserve as well develop strategies preserving fertility. ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ 48 Онкология и Радиология Казахстана, №1 (75) 2025 Methods: involved 80 patients with and 61...
303 Background: Nivolumab in combination with chemotherapy has been approved the first-line treatment of PD-L1-positive metastatic gastric cancer (GC). Fibroblast growth factor receptor 2 (FGFR2) is overexpressed 30% patients GC and a potential new target for targeted therapy monoclonal antibodies 1 or allosteric extracellular inhibitors. The aim NIVOFGFR2 study was to evaluate preliminary efficacy nivolumab co-expressing PD-L1 FGFR2. Methods: In this single-arm, multi-center, phase study,...
293 Background: The growing number of patients with genitourinary (GU) cancers coupled complexity their treatments could create an increasing burden on GU oncologists. Bureau for Cancer Research (BUCARE) assessed the prevalence burnout among Methods: This is a cross-sectional survey study conducted online practicing surgical, medical and radiation oncologists from Kazakhstan, Russia, Uzbekistan, Azerbaijan, Georgia, Kyrgyzstan, Tajikistan, Israel. primary outcome experience through Maslach...
4042 Background: The interim analysis of the NIVOFGFR2 phase 2 study showed a 1-year PFS rate 30.4% in patients with FGFR2-positive, PD-L1-positive metastatic gastric cancer treated combination nivolumab and CAPOX first-line setting (GI ASCO 2024). Here, we present data on overall survival (OS) second-line (PFS2). Methods: In this single-arm, multi-center, study, eligible had untreated HER2-negative adenocarcinoma, their PD-L1 expression (CPS≥5; DAKO 28-8) FGFR2 status (moderate (2+) strong...
<title>Abstract</title> Background Immunotherapy is increasingly significant in treating metastatic gastric cancer. This prospective phase 2 study investigates the efficacy and safety of combining nivolumab with chemotherapy patients cancer co-expressing FGFR2 PD-L1. Methods Eligible were aged 18 years or older, previously untreated HER-2 negative, PD-L1 positive, positive adenocarcinoma. Patients received (360 mg every 3 weeks) combination (CAPOX: capecitabine 1000 mg/m² twice daily on days...
Results: Interestingly, in subgroup analysis of rs1045642 ABCB1 gene, a significant difference was found with greater progression free survival (PFS) the AA homozygous group compared to heterozygous alleles ( p = 0.002, Bonferroni correction).Rs2032582 gene also presented heterogeneous distribution 0.03), showing PFS that clearly favors state.The 7 cases present mean 34.71, 21 state 15.9, and GG presents ILP 23.38 months.RS2242480 encoding CYP3A4 had been CC (29 cases) heterozygosis CT (6...